EA202191462A1 - CYCLIC TETRAMERIC COMPOUNDS AS PROTEIN CONVERTASE INHIBITORS SUBTILYSIN/KEXIN TYPE 9 (PCSK9) FOR THE TREATMENT OF METABOLIC DISORDERS - Google Patents

CYCLIC TETRAMERIC COMPOUNDS AS PROTEIN CONVERTASE INHIBITORS SUBTILYSIN/KEXIN TYPE 9 (PCSK9) FOR THE TREATMENT OF METABOLIC DISORDERS

Info

Publication number
EA202191462A1
EA202191462A1 EA202191462A EA202191462A EA202191462A1 EA 202191462 A1 EA202191462 A1 EA 202191462A1 EA 202191462 A EA202191462 A EA 202191462A EA 202191462 A EA202191462 A EA 202191462A EA 202191462 A1 EA202191462 A1 EA 202191462A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pcsk9
treatment
subtilysin
metabolic disorders
kexin type
Prior art date
Application number
EA202191462A
Other languages
Russian (ru)
Inventor
Карин Брайнер
Брайан Эддисон Декристофер
Алек Натансон Флайер
Андрей Александрович Голосов
Филипп Гроше
Юджин Юэцзинь Лю
Джастин Йик Чинг Мао
Лорен Джилкрист Монович
Таджешь Джейпракаш Пател
Карина Кристина Санчес
Ляньшэн Су
Лихуа Ян
Жуй Чжэн
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Priority claimed from PCT/IB2019/060201 external-priority patent/WO2020110009A1/en
Publication of EA202191462A1 publication Critical patent/EA202191462A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к ингибиторам PCSK9, применимым в лечении заболеваний, связанных с метаболизмом холестерина, липидов, и других заболеваний, в развитии которых участвует PCSK9, имеющим формулу (I)или их фармацевтически приемлемым соли, гидрату, сольвату, пролекарству на его основе, их стереоизомеру, N-оксиду или таутомеру, где R1, R2, R3, R4, R5, R6, R7, R8, R9, X1, X2 и X3 описаны в данном документе.The present invention relates to PCSK9 inhibitors useful in the treatment of diseases associated with the metabolism of cholesterol, lipids, and other diseases in which PCSK9 is involved, having formula (I) or their pharmaceutically acceptable salt, hydrate, solvate, prodrug based on it, their stereoisomer, N-oxide or tautomer, where R1, R2, R3, R4, R5, R6, R7, R8, R9, X1, X2 and X3 are described in this document.

EA202191462A 2019-10-23 2019-11-26 CYCLIC TETRAMERIC COMPOUNDS AS PROTEIN CONVERTASE INHIBITORS SUBTILYSIN/KEXIN TYPE 9 (PCSK9) FOR THE TREATMENT OF METABOLIC DISORDERS EA202191462A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924828P 2019-10-23 2019-10-23
PCT/IB2019/060201 WO2020110009A1 (en) 2018-11-27 2019-11-26 Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
EA202191462A1 true EA202191462A1 (en) 2022-01-25

Family

ID=80631249

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191462A EA202191462A1 (en) 2019-10-23 2019-11-26 CYCLIC TETRAMERIC COMPOUNDS AS PROTEIN CONVERTASE INHIBITORS SUBTILYSIN/KEXIN TYPE 9 (PCSK9) FOR THE TREATMENT OF METABOLIC DISORDERS

Country Status (1)

Country Link
EA (1) EA202191462A1 (en)

Similar Documents

Publication Publication Date Title
EA201992308A1 (en) METHOD FOR PRODUCING 6- (CYCLOPROPANAMIDO) -4 - ((2-METHOXY-3- (1-METHYL-1H-1,2,4-TRIAZOL-3-IL) Phenyl) AMINO) -3- (METHYL-d3) PYRIDAZINE -3-CARBOXAMIDE
EA202091709A1 (en) DNA PC INHIBITORS
EA201790078A1 (en) MNK INHIBITORS AND RELATED METHODS
EA201891229A1 (en) EIF4A-INHIBITING COMPOUNDS AND RELATED METHODS
EA201891191A1 (en) 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION
EA201890086A1 (en) 1,4-substituted derivatives of piperidine
EA202092086A1 (en) ARGINASE INHIBITORS
EA201290894A1 (en) AZETIDINE DERIVATIVES OF PIPERIDIN-4-ILA AS JAK1 INHIBITORS
EA200702339A1 (en) SUBSTITUTED AMIDA DERIVATIVES AS AN INHIBITOR PROTEINKINASE INHIBITORS
EA201790817A1 (en) 2-AMINO-3,5-DIFTOR-3,6-DIMETHYL-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS FOR THE TREATMENT OF ALLZHEIMER'S DISEASE
EA201790818A1 (en) 2-AMINO-6- (DIFTOROMETIL) -5,5-DIFTOR-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS
EA202091708A1 (en) DNA PC INHIBITORS
MX2021002521A (en) Dimethyl amino azetidine amides as jak inhibitors.
EA201991894A1 (en) PIPERIDINE-SUBSTITUTED Mnk INHIBITORS AND RELATED WAYS
EA202192905A1 (en) COMPOUNDS CONTAINING N-METHYL-2-PYRIDONE AND PHARMACEUTICALLY ACCEPTABLE SALTS
EA201890815A1 (en) AMINO ACID COMPOSITIONS WITH MODIFIED DELIVERY FOR ORAL ADMINISTRATION
EA201990678A1 (en) Heteroarylcarboxamide Compounds as Ripk2 Inhibitors
MX2018014164A (en) Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid.
PH12019500569A1 (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
MA32183B1 (en) Hydroxylamine pyrimidylcyclopentane is used as akt protein kinase inhibitors
EA202090959A1 (en) AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS, THEIR SALTS AND METHODS OF THEIR SYNTHESIS
EA201790830A1 (en) ALDOSTERONSYNTASE INHIBITORS
EA201790253A1 (en) ALDOSTERONSYNTASE INHIBITORS
EA201891319A1 (en) COMPOUNDS OF ALKYDYDYDROCHINOLINSULPHONAMIDE
EA201691539A1 (en) 2,7-DIAZASPIRO [3.5] NONANE CONNECTIONS